

EISNERAMPER

**THE AARON DIAMOND
AIDS RESEARCH
CENTER FOR THE CITY OF
NEW YORK, INC.**

**REPORTS IN COMPLIANCE WITH
THE UNIFORM GUIDANCE**

**JUNE 30, 2018 and 2017
(with supplementary schedule)**



**THE AARON DIAMOND AIDS RESEARCH CENTER
FOR THE CITY OF NEW YORK, INC.**

Contents

	<u>Page</u>
Independent Auditors' Report	1
Financial Statements and Compliance Reports	
Statements of financial position as of June 30, 2018 and 2017	3
Statements of activities for the years ended June 30, 2018 and 2017	4
Statements of functional expenses for the years ended June 30, 2018 and 2017	5
Statements of cash flows for the years ended June 30, 2018 and 2017	6
Notes to financial statements	7
Independent auditors' report on internal control over financial reporting and on compliance and other matters based on an audit of financial statements performed in accordance with government auditing standards	20
Independent auditors' report on compliance for its major federal program and on internal control over compliance required by the Uniform Guidance	22
Schedule of findings and questioned costs for the year ended June 30, 2018	24
Supplementary Schedule	
Schedule of expenditures of federal awards for the year ended June 30, 2018	25
Notes to schedule of expenditures of federal awards for the year ended June 30, 2018	26

INDEPENDENT AUDITORS' REPORT

Board of Directors
The Aaron Diamond Aids Research Center
for the City of New York, Inc.
New York, New York

Report on the Financial Statements

We have audited the accompanying financial statements of The Aaron Diamond Aids Research Center for the City of New York, Inc. (the "Center"), which comprise the statements of financial position as of June 30, 2018 and 2017, and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

The Center's management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Aaron Diamond Aids Research Center for the City of New York, Inc. as of June 30, 2018 and 2017, and the changes in its net assets and its cash flows for the years then ended, in accordance with accounting principles generally accepted in the United States of America.



Other Matters - Report on Supplementary

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by Title 2 *U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, and is not a required part of the financial statements. Such information is the responsibility of management and was derived from, and relates directly to, the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain other procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 18, 2018 on our consideration of the Center's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control over financial reporting and compliance.

EisnerAmper LLP

EISNERAMPER LLP
New York, New York
October 18, 2018



THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

Statements of Financial Position

	June 30,	
	2018	2017
ASSETS		
Cash and cash equivalents	\$ 14,031,128	\$ 4,122,093
Grant and contract revenues receivable	1,157,584	1,359,738
Investments	51,704,646	61,215,405
Prepaid expenses and other assets	446,287	601,528
Property and equipment, net	1,998,461	318,557
	<u>\$ 69,338,106</u>	<u>\$ 67,617,321</u>
LIABILITIES AND NET ASSETS		
Liabilities:		
Accounts payable and accrued expenses	\$ 1,418,096	\$ 1,482,593
Grant and contract income received in advance	4,179,104	2,675,376
	<u>5,597,200</u>	<u>4,157,969</u>
Total liabilities		
Commitments and contingency (See Note I)		
Net assets:		
Unrestricted:		
Available for operations	52,202,734	37,775,003
Board-designated		14,471,713
	<u>52,202,734</u>	<u>52,246,716</u>
Total unrestricted		
Temporarily restricted	6,538,172	6,212,636
Permanently restricted	5,000,000	5,000,000
	<u>63,740,906</u>	<u>63,459,352</u>
Total net assets		
	<u>\$ 69,338,106</u>	<u>\$ 67,617,321</u>

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

Statements of Activities

	Year Ended June 30,							
	2018			2017				
	Unrestricted	Temporarily Restricted	Permanently Restricted	Total	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Support and revenue:								
Revenue from scientific activities:								
Restricted scientific grants and contracts	\$ 10,234,577	\$ 74,500		\$ 10,309,077	\$ 10,055,100	\$ 75,000		\$ 10,130,100
Revenue from clinical trials	<u>56,072</u>			<u>56,072</u>	<u>204,271</u>			<u>204,271</u>
	<u>10,290,649</u>	<u>74,500</u>		<u>10,365,149</u>	<u>10,259,371</u>	<u>75,000</u>		<u>10,334,371</u>
Contributions and other revenue:								
Contributions	306,957	40,000		346,957	314,829	17,500		332,329
Investment income	4,263,640	673,061		4,936,701	6,032,117	923,653		6,955,770
Loss on disposal					(34,581)			(34,581)
	<u>4,570,597</u>	<u>713,061</u>		<u>5,283,658</u>	<u>6,312,365</u>	<u>941,153</u>		<u>7,253,518</u>
Total support and revenue before net assets released from restrictions	14,861,246	787,561		15,648,807	16,571,736	1,016,153		17,587,889
Net assets released from restrictions	<u>462,025</u>	<u>(462,025)</u>		<u>0</u>	<u>320,279</u>	<u>(320,279)</u>		<u>0</u>
Total support and revenue	<u>15,323,271</u>	<u>325,536</u>		<u>15,648,807</u>	<u>16,892,015</u>	<u>695,874</u>		<u>17,587,889</u>
Expenses:								
Program:								
Scientific research funded by grants	7,965,448			7,965,448	7,406,824			7,406,824
Research support	1,980,703			1,980,703	2,333,370			2,333,370
Research administration	264,282			264,282	299,418			299,418
Facilities - scientific	<u>2,023,773</u>			<u>2,023,773</u>	<u>1,804,016</u>			<u>1,804,016</u>
Total program expense	<u>12,234,206</u>			<u>12,234,206</u>	<u>11,843,628</u>			<u>11,843,628</u>
Management and general:								
General administration	2,705,672			2,705,672	2,419,460			2,419,460
Facilities - management and general	<u>271,095</u>			<u>271,095</u>	<u>243,093</u>			<u>243,093</u>
Total management and general	<u>2,976,767</u>			<u>2,976,767</u>	<u>2,662,553</u>			<u>2,662,553</u>
Depreciation and amortization	<u>156,280</u>			<u>156,280</u>	<u>168,486</u>			<u>168,486</u>
Total expenses	<u>15,367,253</u>			<u>15,367,253</u>	<u>14,674,667</u>			<u>14,674,667</u>
Change in net assets	(43,982)	325,536		281,554	2,217,348	695,874		2,913,222
Net assets, beginning of year	<u>52,246,716</u>	<u>6,212,636</u>	<u>\$ 5,000,000</u>	<u>63,459,352</u>	<u>50,029,368</u>	<u>5,516,762</u>	<u>\$ 5,000,000</u>	<u>60,546,130</u>
Net assets, end of year	<u>\$ 52,202,734</u>	<u>\$ 6,538,172</u>	<u>\$ 5,000,000</u>	<u>\$ 63,740,906</u>	<u>\$ 52,246,716</u>	<u>\$ 6,212,636</u>	<u>\$ 5,000,000</u>	<u>\$ 63,459,352</u>

See notes to financial statements.

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

Statements of Functional Expenses

	Year Ended June 30,					
	2018			2017		
	Program Services	Management and General	Total	Program Services	Management and General	Total
Salaries	\$ 3,477,425	\$ 1,302,342	\$ 4,779,767	\$ 4,160,178	\$ 1,338,945	\$ 5,499,123
Employee benefits and payroll taxes	1,688,511	833,271	2,521,782	1,673,562	549,203	2,222,765
Laboratory supplies	837,860		837,860	1,152,395		1,152,395
Core facilities expense	94,914		94,914	198,150		198,150
Animal services	152,010		152,010	200,222		200,222
Professional fees	476,152	572,177	1,048,329	481,039	531,096	1,012,135
Office expense	78,512	13,966	92,478	64,792	23,275	88,067
Occupancy expense	986,228	159,298	1,145,526	830,157	134,591	964,748
Insurance expense	266,550	42,197	308,747	271,681	43,009	314,690
Telecommunications	35,887	12,853	48,740	39,931	12,743	52,674
Travel and meetings	229,144	33,312	262,456	157,536	23,961	181,497
Books and subscriptions	8,118	5,079	13,197	18,990	3,441	22,431
Maintenance expenses	308,895	2,272	311,167	315,088	2,289	317,377
Radiation safety and disposal	17,855		17,855	10,761		10,761
Sub-contracts	3,576,145		3,576,145	2,269,146		2,269,146
	12,234,206	2,976,767	15,210,973	11,843,628	2,662,553	14,506,181
Depreciation and amortization	123,461	32,819	156,280	133,105	35,381	168,486
	<u>\$ 12,357,667</u>	<u>\$ 3,009,586</u>	<u>\$ 15,367,253</u>	<u>\$ 11,976,733</u>	<u>\$ 2,697,934</u>	<u>\$ 14,674,667</u>

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

Statements of Cash Flows

	Year Ended June 30,	
	<u>2018</u>	<u>2017</u>
Cash flows from operating activities:		
Change in net assets	\$ 281,554	\$ 2,913,222
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Depreciation and amortization	156,280	168,486
Loss on disposal of property and equipment		34,581
Net realized and unrealized losses (gains) on investments	243,104	(5,519,500)
Changes in:		
Grant and contract revenues receivable	202,154	312,022
Prepaid expenses and other assets	155,241	(217,829)
Accounts payable and accrued expenses	(64,497)	(840,565)
Grant and contract income received in advance	<u>1,503,728</u>	<u>(2,261,443)</u>
Net cash provided by (used in) operating activities	<u>2,477,564</u>	<u>(5,411,026)</u>
Cash flows from investing activities:		
Purchases of investments	(8,595,014)	(3,054,091)
Proceeds from sales and maturities of investments	17,862,669	4,957,125
Purchases of property and equipment	<u>(1,836,184)</u>	<u> </u>
Net cash provided by investing activities	<u>7,431,471</u>	<u>1,903,034</u>
Change in cash and cash equivalents	9,909,035	(3,507,992)
Cash and cash equivalents, beginning of year	<u>4,122,093</u>	<u>7,630,085</u>
Cash and cash equivalents, end of year	<u>\$ 14,031,128</u>	<u>\$ 4,122,093</u>

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

Notes to Financial Statements June 30, 2018 and 2017

NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

[1] Organization:

The Aaron Diamond AIDS Research Center for the City of New York, Inc. (the "Center"), incorporated in New York in 1988, is a research institute which houses a specialized viral containment laboratory where the HIV virus can be grown and biomedical research is undertaken.

The Center is exempt from federal income tax pursuant to Section 501(c)(3) of the U.S. Internal Revenue Code (the "Code") and from state and local taxes under comparable laws.

In fiscal year 2018 the Center's Board of Directors entered into negotiations with Columbia University ("Columbia") in which the Center would transfer substantially all of its assets to Columbia and Columbia would assume certain of the liabilities of the Center in connection with an integration of the Center's operations into Columbia. Upon closing of the transaction, the Center's activities and operations would relocate to Columbia as the Aaron Diamond AIDS Research Center within the Columbia University College of Physicians and Surgeons, for the purpose, amongst other things, combining the strengths of the institutions to enhance research and teaching in the area of HIV/AIDS, immunology and retro viruses. The Board approved the transaction subsequent to June 30, 2018.

[2] Basis of accounting:

The accompanying financial statements of the Center have been prepared using the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") as applicable to not-for-profit organizations.

[3] Use of estimates:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as the disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

[4] Cash and cash equivalents:

For financial reporting purposes, the Center considers all highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents.

[5] Investments:

The Center's investments in mutual funds and fixed income securities are reported at their fair values in the statements of financial position based on quoted market prices.

The Center also has investments in limited partnerships and limited liability companies which are considered to be alternative investments, for which readily determinable fair values do not exist. The underlying holdings of the Center's alternative investments consist principally of publicly traded domestic and international equity securities. The fair value of the alternative investments has been estimated based on the respective net asset value ("NAV") per share (or its equivalent unit) of each investment, as reported by the particular investment manager. Investments in limited partnerships and/or limited liability companies where NAV cannot be used as a practical expedient to fair value are valued based on the valuation policies and procedures of the general partners. The general partners perform oversight of the underlying positions, both on an investment level and from a risk perspective. The general partners are also responsible for ensuring that the investments are valued according to the policies and procedures adopted by the partnerships. The Center places reliance upon those procedures, and it records those investments at fair value as determined by the general partners.

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

Notes to Financial Statements June 30, 2018 and 2017

NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[5] Investments: (continued)

Because of the complex management structures and nature of the underlying investments and the inherent uncertainty of the valuation of the alternative investments, the Center's management and its various investment managers monitor their positions to reduce the risk of potential losses due to changes in fair values or the failure of counterparties to perform on a routine basis. Management believes the carrying amount of the investments in non-publicly traded securities is a reasonable estimate of their fair value. However, such estimated fair values may differ significantly from the values that would have been used had a ready market for these investments existed.

The Center's investments, in general, are subject to various risks, such as interest-rate, market, and credit risks. Due to the level of risk associated with certain investment vehicles, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

Certain of the Center's investment managers enter into derivatives contracts held or issued for trading purposes. These investments are subject to various market risks, which arise from changes in securities values and other market conditions. As part of their overall trading strategies, the investment managers may engage in the purchases and sales of index and equity options, for the purpose of generating profit and/or reducing market risk. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the accompanying financial statements.

Investment transactions are recorded on a trade-date basis. Realized gains and losses on investments sold, and unrealized appreciation and depreciation on investments held, are reported in the statements of activities as increases or decreases in unrestricted net assets unless their use is restricted on a temporary or permanent basis through donor stipulation. Realized gains and losses on investments are determined by comparison of the cost of acquisition to proceeds at the time of disposition. Distributions from limited partnerships and limited liability companies that represent returns of contributed capital reduce the cumulative costs basis of the respective investment. Distributions received from limited partnerships and limited liability companies in excess of the Center's cumulative cost basis are recognized as realized gains. Unrealized gains and losses on investments are determined by comparing the investment's cost to the fair value at the end of each year. The earnings from dividends and interest are recognized when earned.

Donated securities are recorded at their estimated fair values, as determined by the proceeds received on the dates of donation or by their net asset values as determined by the Center's management. The Center's policy is to sell the donated securities immediately, and, accordingly, for purposes of the statement of cash flows, donated securities and the proceeds generated from their sale are included within operating activities. With respect to donors' contributions of equity securities, which for example, are (i) not readily marketable, (ii) the securities of private companies, or (iii) the securities of companies in liquidation, the Center's policy is to record such items at appraised value at time of donation in the absence of readily determinable fair values, although such assets may have significant value.

Investment expenses include the services of bank trustees, investment managers and custodians. The balances of investment management fees disclosed in Note B are those specific fees charged by the Center's various investment managers in each fiscal year; however, they do not include those fees that are embedded in various other investment accounts and transactions.

The Center participates in a securities lending program sponsored by the Northern Trust Corporation ("Northern Trust"). Under this program, Northern Trust lends securities, including those of the Center, to qualified institutional borrowers. In addition to the program fees that they pay, the borrowers place assets with a value greater than the market value of the securities borrowed into a collateral pool. The investment of the assets in the collateral pool provides an additional return to lending-program participants such as the Center.

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

Notes to Financial Statements June 30, 2018 and 2017

NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[6] Property and equipment:

Property and equipment are stated at their original cost at the dates of acquisition, or, if contributed, at their fair values at the dates of donation. The Center capitalizes items of property and equipment that have a cost of \$5,000 or more and useful lives greater than one year, whereas the costs for minor repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over seven years, the estimated useful lives of the related assets. Leasehold improvements are amortized over the remaining lease term, or the useful lives of the improvements, whichever is shorter.

Management evaluates the recoverability of the investment in long-lived assets on an on-going basis and recognizes any impairment in the year of determination. Long-lived assets were tested for impairment as of June 30, 2018 and 2017, respectively, and, in the opinion of management, there were no impairments. It is reasonably possible that relevant conditions could change in the near term and necessitate a change in management's estimate of the recoverability of these assets.

[7] Accrued vacation:

Accrued vacation is included as a liability in the accompanying financial statements and represents the Center's obligation for the cost of unused employee vacation time payable in the event of employee departures; the obligation is recalculated every year. At June 30, 2018 and 2017, the accrued vacation obligation was approximately \$667,000 and \$477,000, respectively, and was reported as part of accounts payable and accrued expenses in the accompanying statements of financial position.

[8] Net assets:

(i) *Unrestricted:*

Unrestricted net assets represent those resources that are not subject to donor restrictions and are available for current operations. A portion of the Center's resources devoted to scientific activities, as well as its property and equipment and its quasi-endowment fund, are presented as unrestricted as there are no donor or grantor restrictions on the use of these assets.

The quasi-endowment (board-designated) fund was formed in 1999 through the segregation by the Board of Directors of \$6,500,000 of unrestricted funds (derived from the sale of an investment). The Board's resolution establishing this fund provides that the principal and earnings are to be invested and that, after the second year of the fund's existence, an amount equal to 5% of its average net-asset value (for the three preceding years) may be utilized for Center operations.

In fiscal-year 2018, in expectation of the Columbia transaction costs (See Note A[1]), the Board passed a resolution, removing the restriction on the quasi-endowment. Therefore, the funds were unrestricted assets and available for operations.

(ii) *Temporarily restricted:*

Temporarily restricted net assets represent those resources that are subject to the requirements of the New York Prudent Management of Institutional Funds Act ("NYPMIFA") and the use of which has been restricted by donors or state law to specific purposes and/or the passage of time. When a donor restriction expires, that is, when a stipulated time restriction ends, or a purpose restriction is accomplished or funds are appropriated through an action of the Board of Directors, temporarily restricted net assets are reclassified as unrestricted net assets and reported in the accompanying statements of activities as "net assets released from restrictions."

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

Notes to Financial Statements June 30, 2018 and 2017

NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[8] Net assets: (continued)

(iii) *Permanently restricted:*

Permanently restricted net assets represent those resources the principal of which is originally restricted into perpetuity by its donor, the Irene Diamond Fund. The purposes for which the income and net capital appreciation arising from the underlying assets may be used depend on the wishes of that donor. Under the terms of NYPMIFA, those earnings are classified as temporarily restricted in the accompanying statements of activities, pending appropriation by the Board of Directors.

[9] Revenue recognition:

(i) *Scientific grants and contracts:*

Revenue from scientific grants and contracts is recognized as earned through the performance of research services. The asset "grant and contract revenues receivable" is derived from revenues earned and is either billed or unbilled pursuant to the terms of the specific grants or contracts. The liability "grant and contract income received in advance" is derived from amounts collected prior to the performance of research services and which is subsequently recorded as revenue when such services are performed.

(ii) *Contributions and pledges:*

Contributions to the Center are recognized as revenue upon the receipt of cash or other assets or of unconditional pledges. Contributions are recorded as either temporarily or permanently restricted if they are received with donor stipulations or time considerations as to their use. Conditional contributions are recorded when the conditions have been met, and, if received in advance, are recognized in the statements of financial position as funds received in advance. The Center records bequest income at the time it has an established right to a bequest and the proceeds are measurable. Contributions to be received over periods longer than a single year are discounted at an interest rate commensurate with the risk involved.

[10] Functional allocation of expenses:

The cost of providing the various programs and supporting services have been summarized on a functional basis in the accompanying statements of activities and functional expenses. Accordingly, certain costs have been allocated by management among the program, management and general, and fund-raising categories, using appropriate measurement methodologies.

[11] Income taxes:

The Center is subject to the provisions of the Financial Accounting Standards Board's (the "FASB") Accounting Standards Codification ("ASC") Topic 740, *Income Taxes*, relating to accounting and reporting for uncertainty in income taxes. Because of the Center's general tax-exempt status, management believes ASC Topic 740 has not had, and is not anticipated to have, a material impact on the Center's financial statements.

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

**Notes to Financial Statements
June 30, 2018 and 2017**

NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[12] Upcoming accounting changes:

In August 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-14, *Presentation of Financial Statements of Not-for-Profit Entities*. ASU 2016-14 amends financial-statement presentations and disclosures, with the goal of assisting not-for-profit organizations in providing more relevant information about their resources (and the changes in those resources) to donors, grantors, creditors, and other users. ASU 2016-14 includes qualitative and quantitative requirements in the following areas: (i) net asset classifications, (ii) investment returns, (iii) expense categorizations, (iv) liquidity and the availability of resources, and (v) the presentation of operating cash flows. The new standard will be effective for annual reporting periods beginning after December 15, 2017. The Center will adopt the accounting pronouncement in fiscal-year 2019.

[13] Subsequent events:

The Organization evaluated subsequent events through October 18, 2018, the date the financial statements were available to be issued.

NOTE B - INVESTMENTS

At each fiscal year-end, investments consisted of the following:

	June 30,			
	2018		2017	
	Fair Value	Cost	Fair Value	Cost
Multi-asset mutual fund	\$ 27,950,820	\$ 28,016,333	\$ 34,034,003	\$ 31,809,643
U.S. government bonds	2,260,707	2,270,237	2,226,065	2,108,097
Limited partnerships	630,896	1,637,411	671,970	1,680,718
Equity security funds-of-funds	13,000,728	3,079,102	15,370,385	4,881,715
Other hedge funds-of-funds	7,861,495	4,360,131	8,912,982	5,434,150
	<u>\$ 51,704,646</u>	<u>\$ 39,363,214</u>	<u>\$ 61,215,405</u>	<u>\$ 45,914,323</u>

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

Notes to Financial Statements June 30, 2018 and 2017

NOTE B - INVESTMENTS (CONTINUED)

As disclosed above, concentration of the Center's investments in excess of 10% of the fair value of its portfolio included approximately (i) 54% invested in multi-asset mutual fund, (ii) 25% invested in equity security funds-of-funds, and (iii) 15% invested in other hedge funds-of-funds.

During each fiscal year, investment income (loss) consisted of the following:

	Year Ended June 30,	
	2018	2017
Interest and dividends	\$ 5,179,805	\$ 1,436,270
Net realized gains	2,716,546	427,015
Net unrealized (losses) gains	<u>(2,959,650)</u>	<u>5,092,485</u>
	4,936,701	6,955,770
Less: investment management fees	<u>(187,700)</u>	<u>(125,554)</u>
Net investment income	<u>\$ 4,749,001</u>	<u>\$ 6,830,216</u>

Investment management fees were included in professional fees in the accompanying statements of functional expenses for both fiscal-years 2018 and 2017.

The FASB's ASC Topic 820, *Fair Value Measurements*, establishes a three-level valuation hierarchy of fair-value measurements. These valuation techniques are based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. These two types of inputs create the following fair-value hierarchy:

- Level 1: Valuations are based on observable inputs that reflect quoted market prices in active markets for those investments at the reporting date.
- Level 2: Valuations are based on (i) quoted prices for similar investments in active markets, or (ii) quoted prices for those investments, or similar investments, in markets that are not active, or (iii) pricing inputs other than quoted prices that are directly or indirectly observable at the reporting date.
- Level 3: Valuations are based on pricing inputs that are unobservable and include situations where (i) there is little, if any, market activity for the investments, or (ii) the investments cannot be independently valued.

Certain of the Center's investments are valued using NAV (or its equivalent) as a practical expedient of fair value. This applies to investments which (i) do not have a readily determinable fair value and (ii) the financial statements of which were prepared by the respective investment managers, in a manner consistent with the measurement principles of either an investment company or an entity which has the attributes of an investment company. Investments that are valued using NAV (or its equivalent unit) are not required to be categorized within the fair value hierarchy and accordingly, have been excluded from the fair value hierarchy.

The Center's investments are subject to various risks, such as interest-rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

**Notes to Financial Statements
June 30, 2018 and 2017**

NOTE B - INVESTMENTS (CONTINUED)

The availability of market data is monitored to assess the appropriate classification of financial instruments within the fair-value hierarchy. Changes in economic conditions or valuation techniques may require the transfer of financial instruments from one level to another. In such instances, the transfer is reported at the beginning of the reporting period. For fiscal-years 2018 and 2017, there were no transfers among the fair-value-hierarchy levels.

The following table summarizes the fair values of the Center's assets at each fiscal year-end, in accordance with the ASC Topic 820 valuation levels:

	June 30, 2018				
	Fair-value Hierarchy			Measured at NAV	Total Investments
	Level 2	Level 3	Total		
Multi-asset mutual fund	\$ 27,950,820		\$ 27,950,820		\$ 27,950,820
U.S. government bonds	2,260,707		2,260,707		2,260,707
Limited partnerships		\$ 630,896	630,896		630,896
Equity security funds-of-funds				\$ 13,000,728	13,000,728
Other hedge funds-of-funds				7,861,495	7,861,495
	<u>\$ 30,211,527</u>	<u>\$ 630,896</u>	<u>\$ 30,842,423</u>	<u>\$ 20,862,223</u>	<u>\$ 51,704,646</u>

	June 30, 2017				
	Fair-value Hierarchy			Measured at NAV	Total Investments
	Level 2	Level 3	Total		
Multi-asset mutual fund	\$ 34,034,003		\$ 34,034,003		\$ 34,034,003
U.S. government bonds	2,226,065		2,226,065		2,226,065
Limited partnerships		\$ 671,970	671,970		671,970
Equity security funds-of-funds				\$ 15,370,385	15,370,385
Other hedge funds-of-funds				8,912,982	8,912,982
	<u>\$ 36,260,068</u>	<u>\$ 671,970</u>	<u>\$ 36,932,038</u>	<u>\$ 24,283,367</u>	<u>\$ 61,215,405</u>

The following summarizes the changes in fair-values of the Center's Level 3 investments for each fiscal-year:

	June 30,	
	2018	2017
Beginning balance	\$ 671,970	\$ 1,135,158
Redemptions	(103,394)	(639,396)
Realized gains	60,088	11,052
Unrealized gains (losses)	<u>2,232</u>	<u>165,156</u>
Ending balance	<u>\$ 630,896</u>	<u>\$ 671,970</u>

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

**Notes to Financial Statements
June 30, 2018 and 2017**

NOTE B - INVESTMENTS (CONTINUED)

The following table describes the funding commitment and redemption information for the Center's limited liability partnerships and limited liability companies:

	June 30, 2018			
	<u>Fair Value</u>	<u>Unfunded Commitments</u>	<u>Redemption Frequency</u>	<u>Redemption Notice Period</u>
Limited liability partnerships	\$ 630,896	\$ 0	None- in	N/A
Limited liability companies	<u>20,862,223</u>	<u>0</u>	Quarterly	90 Days
	<u>\$ 21,493,119</u>	<u>\$ 0</u>		

NOTE C - RECEIVABLES

Grant and contract revenues receivable were \$1,157,584 and \$1,359,738 for fiscal-years 2018 and 2017, respectively. Based on its prior experience with grantors, management expects all receivables to be fully collectible. Accordingly, no provision for doubtful accounts has been recorded.

NOTE D - PROPERTY AND EQUIPMENT

At each fiscal year-end, property and equipment consisted of the following:

	June 30,	
	<u>2018</u>	<u>2017</u>
Leasehold improvements	\$ 19,087,169	\$ 19,087,169
Equipment and laboratory accessories	1,945,766	5,722,432
Office furniture and equipment	<u>2,576,660</u>	<u>3,554,304</u>
	23,609,595	28,363,905
Less accumulated depreciation and amortization	<u>(22,978,952)</u>	<u>(28,045,348)</u>
	630,643	318,557
Construction in progress	<u>1,367,818</u>	<u> </u>
	<u>\$ 1,998,461</u>	<u>\$ 318,557</u>

During fiscal-year 2018, the Center wrote off fully depreciated equipment and laboratory accessories and office furniture and equipment of \$5,222,676. Construction in progress represents architect and engineering costs associated with the buildout of the office and laboratory space at Colombia (See Note A[1]).

During fiscal-year 2017, the Center wrote off equipment and laboratory accessories and office furniture and equipment of \$104,792 and recognized a loss on disposal of \$34,581.

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

**Notes to Financial Statements
June 30, 2018 and 2017**

NOTE E - REVENUE FROM SCIENTIFIC ACTIVITIES

During each fiscal-year, revenue from scientific activities consisted of the following:

	Year Ended June 30,	
	2018	2017
National Institutes of Health:		
Direct programs	\$ 3,774,839	\$ 4,719,261
Grants passed through various universities	1,097,596	1,986,498
Non-governmental grants	5,373,933	2,979,953
Chinese AIDS Initiative and other	62,709	444,388
Revenue from clinical trials	56,072	204,271
	<u>\$ 10,365,149</u>	<u>\$ 10,334,371</u>

The Center's management and general expenses and its depreciation expense form the basis for its overhead calculation. The cost of such overhead is recovered from grantors at rates authorized by them and is included in the Center's grant and contract revenue. For each fiscal year, the following revenue was recognized with respect to overhead:

	Year Ended June 30,	
	2018	2017
National Institutes of Health:		
Direct programs	\$ 1,728,408	\$ 1,710,989
Grants passed through various universities	514,122	925,360
Non-governmental grants	397,491	332,388
Chinese AIDS Initiative and other	108,644	201,584
	<u>\$ 2,748,665</u>	<u>\$ 3,170,321</u>

NOTE F - EMPLOYEE-BENEFIT PLANS

[1] Defined-contribution 403(b) retirement plan:

The Center maintains a defined-contribution retirement plan, established under Section 403(b) of the Code. The plan requires the Center to contribute an amount equal to 15% of the compensation of all eligible employees. In addition, employees may make voluntary contributions to the plan. Total plan expense for fiscal-years 2018 and 2017 was approximately \$602,000 and \$645,000, respectively.

[2] Deferred-compensation 457(b) retirement plan:

The Center established a deferred-compensation plan under Section 457(b) of the Code for certain eligible employees, defined by the Center as its executive team. Under the terms of the plan, eligible employees may contribute amounts through a salary-reduction agreement. Total plan expense for fiscal-years 2018 and 2017 was approximately \$56,000 and \$36,000, respectively.

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

Notes to Financial Statements June 30, 2018 and 2017

NOTE F - EMPLOYEE-BENEFIT PLANS (CONTINUED)

[3] Health insurance:

The Center provides health insurance benefits to all of its employees through a partially self-funded plan. The plan is administered by a third party. The Center self-funds the cost of the program up to specified stop-loss insurance limits. Coverage during the policy period limits the maximum individual and aggregate losses. Self-insurance costs are accrued based upon the aggregate of the liability for reported claims and an estimated liability for claims incurred but not reported. The reserve was approximately \$209,000 and \$130,000 at June 30, 2018 and 2017, respectively and is included in accounts payable and accrued expenses.

NOTE G - TEMPORARILY RESTRICTED NET ASSETS

At each fiscal year-end, temporarily restricted net assets (including allocation of investment gains and losses) were categorized as follows:

	Year Ended June 30,	
	2018	2017
AIDS vaccine research	\$ 3,370,814	\$ 3,437,941
Accumulated endowment income reserved for appropriation	<u>3,167,358</u>	<u>2,774,695</u>
	<u>\$ 6,538,172</u>	<u>\$ 6,212,636</u>

Net assets of \$462,025 and \$320,279 were released from restrictions for AIDS vaccine research during each fiscal-year ended June 30, 2018 and 2017, respectively.

NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS

[1] The endowments:

At June 30, 2017, the Center's endowment consists of both a donor-restricted endowment fund and a fund designated by the Board of Directors to function as endowment. As disclosed in Note A[8](i), in fiscal-year 2018, the Board removed the restriction on the quasi-endowment. Therefore, at June 30, 2018, the Center's endowment consisted of only a donor-restricted fund.

[2] Interpretation of relevant law:

NYPMIFA is applicable to the Center's institutional funds, including its donor-restricted and board-designated endowment funds. The Board of Directors adheres to NYPMIFA's requirements.

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

**Notes to Financial Statements
June 30, 2018 and 2017**

NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS (CONTINUED)

[3] Endowment net-asset composition by type of fund for each year was as follows:

	<u>June 30, 2018</u>		
	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
Donor-restricted endowment fund	\$ 3,167,358	\$ 5,000,000	\$ 8,167,358
Board-designated endowment fund			
Total funds	<u>\$ 3,167,358</u>	<u>\$ 5,000,000</u>	<u>\$ 8,167,358</u>

	<u>June 30, 2017</u>			
	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
Donor-restricted endowment fund		\$ 2,774,695	\$ 5,000,000	\$ 7,774,695
Board-designated endowment fund	\$ 14,471,713			14,471,713
Total funds	<u>\$ 14,471,713</u>	<u>\$ 2,774,695</u>	<u>\$ 5,000,000</u>	<u>\$ 22,246,408</u>

Temporarily restricted endowment represents that portion of allocated investment income derived from permanently restricted endowment assets that has not been appropriated by the Board of Directors for expenditure.

[4] Changes in endowment net assets for each year were as follows:

	<u>June 30, 2018</u>			
	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
Endowment net assets, beginning of year	\$ 14,471,713	\$ 2,774,695	\$ 5,000,000	\$ 22,246,408
Investment gain		392,663		392,663
Appropriation of endowment assets for expenditure	<u>(14,471,713)</u>			<u>(14,471,713)</u>
Endowment net assets, end of year	<u>\$ 0</u>	<u>\$ 3,167,358</u>	<u>\$ 5,000,000</u>	<u>\$ 8,167,358</u>

	<u>June 30, 2017</u>			
	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
Endowment net assets, beginning of year	\$ 13,709,163	\$ 2,200,226	\$ 5,000,000	\$ 20,909,389
Investment gain	1,499,821	574,469		2,074,290
Appropriation of endowment assets for expenditure	<u>(737,271)</u>			<u>(737,271)</u>
Endowment net assets, end of year	<u>\$ 14,471,713</u>	<u>\$ 2,774,695</u>	<u>\$ 5,000,000</u>	<u>\$ 22,246,408</u>

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

Notes to Financial Statements June 30, 2018 and 2017

NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS (CONTINUED)

[5] Funds with deficiencies:

Due to unfavorable market fluctuations, from time to time the fair value of assets associated with individual donor-restricted endowment funds may decline below the historical dollar value of the donor's original, permanently restricted contribution. Under the terms of NYPMIFA, the Center has no responsibility to restore such decrease in value. There were no such deficiencies in fiscal years 2018 and 2017.

[6] Return objectives and risk parameters:

The Center's endowment assets are invested in a manner intended to produce a positive return on invested assets, while assuming a moderate level of investment risk. Actual returns in any given year may vary, depending on investment strategies and economic conditions.

[7] Strategies employed for achieving objectives:

To satisfy its long-term rate-of-return objectives, the Center relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Center targets a diversified asset allocation that places a greater emphasis on equity-based investments to achieve its long-term return objectives within prudent risk constraints.

[8] Spending policy and how the investment objectives relate to the spending policy:

The permanently restricted endowment is expected to remain whole with all gains and losses reserved in temporarily restricted net assets until appropriated. The objective of the quasi-endowment fund is to utilize 5% of the unrestricted fund balance for operating purposes, with the anticipation that the quasi-endowment fund will grow over time. As disclosed in Note A[8](i), the Board removed the restrictions on the quasi-endowment fund in 2018.

NOTE I - COMMITMENTS AND CONTINGENCY

[1] Lease of premises:

The Center's lease of two floors of a building located in New York City ended on September 30, 2015. The Center has been in ongoing negotiations with the City of New York regarding the execution of a new lease; however, no agreement has been reached. As a result, the Center has remained on a month-to-month lease renewal program.

Rent expense for fiscal-years 2018 and 2017 was approximately \$806,000 and \$685,000, respectively.

[2] Facility contract:

The Center has a facility-management contract ending December 31, 2018.

[3] Employment agreement:

In September 2017, the Center entered into an employment agreement with its executive director which expires in October 2022 or the date the Columbia transaction is completed.

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

**Notes to Financial Statements
June 30, 2018 and 2017**

NOTE I - COMMITMENTS AND CONTINGENCY (CONTINUED)

[4] Other contracts:

In the normal course of business, the Center enters into various contracts for professional and other services, which are typically renewable on a year-to-year basis.

[5] Government-funded activities:

Government-funded activities are subject to audit by the applicable granting agencies. At June 30, 2018, there were no material obligations outstanding as a result of such audits, and management believes that unaudited projects would not result in any material obligations.

NOTE J - CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Center to concentrations of credit risk consist principally of cash and cash-equivalent accounts deposited in financial institutions, the balances of which, from time to time, may exceed federal insurance limits. However, management believes that the Center does not face a significant risk of loss on these accounts due to failures of those institutions.

EISNERAMPER
LLP

INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

Board of Directors
The Aaron Diamond Aids Research Center
for the City of New York, Inc.
New York, New York

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of The Aaron Diamond Aids Research Center for the City of New York, Inc. (the "Center"), which comprise the statement of financial position as of June 30, 2018, the related statements of activities, functional expenses and cash flow for the years then ended, and the related notes to the financial statements, and have issued our report thereon dated October 18, 2018.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Center's internal control over financial reporting ("internal control") to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Center's internal control. Accordingly, we do not express an opinion on the effectiveness of the entity's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over financial reporting was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit, we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Center's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with, which could have a direct and material effect on the determination of financial-statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance, and the results of that testing, and not to provide an opinion on the effectiveness of the Center's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

EisnerAmper LLP

EISNERAMPER LLP
New York, New York
October 18, 2018

EISNERAMPER
LLP



INDEPENDENT AUDITORS' REPORT ON COMPLIANCE FOR ITS MAJOR FEDERAL PROGRAM AND ON INTERNAL CONTROL OVER COMPLIANCE REQUIRED BY THE UNIFORM GUIDANCE

Board of Directors
The Aaron Diamond Aids Research Center
for the City of New York, Inc.
New York, New York

Report on Compliance for Its Major Federal Program

We have audited The Aaron Diamond Aids Research Center for the City of New York, Inc.'s (the "Center") compliance with the types of compliance requirements described in the Office of Management and Budget ("OMB") *Compliance Supplement* that could have a direct and material effect on the Center's major federal program for the year ended June 30, 2018. The Center's major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for the Center's major federal program, based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 *U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* ("Uniform Guidance"). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the Center's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for the major federal program. However, our audit does not provide a legal determination of the Center's compliance.

Opinion on Major Federal Program

In our opinion, the Center complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended June 30, 2018.



Report on Internal Control Over Compliance

Management of the Center is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the Center's internal control over compliance with the types of requirements that could have a direct and material effect on the major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for the major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Center's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or to detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

EisnerAmper LLP

EISNERAMPER LLP
New York, New York
October 18, 2018



THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

**Schedule of Findings and Questioned Costs
Year Ended June 30, 2018**

Section I - Summary of Auditors' Results

Financial Statements

Type of report the auditor issues on whether the financial statements audited were prepared in accordance with U.S. GAAP: Unmodified

Internal control over financial reporting:

Material weaknesses identified: No
Significant deficiencies identified: None reported

Noncompliance material to financial statements noted: No

Federal Awards

Internal control over major programs:

Material weaknesses identified: No
Significant deficiencies identified: None reported

Type of auditors' report issued on compliance for major programs: Unmodified

Any audit findings disclosed that are required to be reported in accordance with Title 2 U.S. Code of Federal Regulations Part 200, Section 516 (a): No

Identification of major program:

CFDA Number	Name of Federal Program
--------------------	--------------------------------

Research and Development - Cluster	
------------------------------------	--

Dollar threshold used to distinguish between Type A and Type B programs: \$750,000

Auditee qualified as low-risk auditee: Yes

Section II - Financial Statements Findings

No matters reported for the year ended June 30, 2018.

Section III - Federal Award Findings and Questioned Costs

No matters reported for the year ended June 30, 2018.

Section IV - Prior Period Findings

No matters reported in prior year.

SUPPLEMENTARY SCHEDULE

EISNERAMPER
LLP

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

**Schedule of Expenditures of Federal Awards
Year Ended June 30, 2018**

<u>Federal Agency/Programs</u>	<u>Federal CFDA#</u>	<u>Contract/Pass-Through Entity Identifying Number</u>	<u>Passed Through to Subrecipients</u>	<u>Federal Expenditures</u>
Research and Development - Cluster:				
U.S. Department of Health and Human Services:				
Drug Abuse and Addiction Research	93.279			\$ 92,071
Allergy, Immunology and Transplantation Research	93.855		<u>\$ 195,113</u>	4,074,985
Mental Health Research:				
Pass-through from Hunter College	93.242	MH-106380		<u>136,301</u>
Total U.S. Department of Health and Human Services			<u>195,113</u>	<u>4,303,357</u>
U.S. Department of Defense:				
Pass-through from Emory University	12.910	T315730		<u>569,078</u>
Total U.S. Department of Defense				<u>569,078</u>
			<u>\$ 195,113</u>	<u>\$ 4,872,435</u>

EISNER AMPER
LLP

THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC.

**Notes to Schedule of Expenditures of Federal Awards
Year Ended June 30, 2018**

NOTE A - BASIS OF PRESENTATION

The accompanying schedule of expenditures of federal awards (the "Schedule") includes the federal award activity of the Center under programs of the federal government for the year ended June 30, 2018. The information in this Schedule is presented in accordance with the requirements of Title 2 *U.S. Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* ("Uniform Guidance"). Because the Schedule presents only a selected portion of the operations of the Center, it is not intended to and does not present the financial position, changes in net assets, or cash flows of the Center.

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. The Center has elected not to use the 10-percent de minimus indirect cost rate as allowed under the Uniform Guidance.

EISNERAMPER
LLP